News & Updates

Diets high in polyunsaturated fatty acid (PUFA) demonstrate slightly greater benefits over high monounsaturated fatty acid (MUFA) diets in reducing blood lipids, reports a study.

Treatment with zanidatamab combined with tislelizumab and/or chemotherapy (CT) significantly improves progression-free survival (PFS) in patients with HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA), as shown in the primary analysis from HERIZON-GEA-01.

A recent study has observed delays in hypertension diagnosis, which potentially results in hospital visits and other cardiovascular diagnoses.

In the treatment of patients with relapsed or refractory follicular lymphoma, adding tafasitamab to lenalidomide and rituximab appears to improve progression-free survival (PFS) while having an acceptable safety profile, according to the phase III inMIND study.

Combining S-1 and oxaliplatin (SOX) as an adjuvant chemotherapy significantly improves overall survival (OS) and disease-free survival (DFS) compared with S-1 alone in patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, according to the final results of the CAPITAL trial presented at ASCO GI 2026.

A novel nested tracheal tube device that reduces localized pressure on oral tissues during mechanical ventilation appears to mitigate the risk of mucosal membrane pressure injuries (MMPIs) and improve overall oral health outcomes.

Dual anti-HER2 blockade with a chemotherapy-free backbone of palbociclib plus letrozole may serve as an alternative treatment to patients with HR-positive/HER2-positive early breast cancer, suggests the phase II TOUCH study, noting similar rates of pathological complete response (pCR) to that of paclitaxel.